Treating diabetes with incretin hormones - Clinical experience

Pediatric Endocrinology Reviews

Volumn 5, Issue 4, 2008, Pages 897-903

  Handelsman, Yehuda ^a  

^a Metabolic Institute of America   (United States)

Author keywords

Diabetes mellitus type 2; DPP 4; Exenatide; GLP 1; Incretins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INCRETIN; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE 1;

ADD ON THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED RELEASE FORMULATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; WEIGHT GAIN; AMINO ACID SEQUENCE; CHILD; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANTIGENS, CD26; CHILD; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MOLECULAR SEQUENCE DATA;

EID: 49049116204     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Centers for Disease Control and Prevention (CDC). Incidence of diabetes. Available at: http://www.cdc.gov/diabetes/statistics/incidence. Accessed March 15, 2008
2. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care 2003;31(3):596-615
3. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
4. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117
5. The UKPDS Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
6. Stratton IM, Adler AI, Neil H, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412
7. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20
8. ACE/AACE consensus conference on the implementation of outpatient management of Diabetes Melitus. Endocr Pract 2006;12(Suppl 1)
9. Turner RC, Cull CA, Frighi V, Holman RR, UK Prospective Diabetes Study Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281(21):2005-2012
10. International Diabetes Federation. Diabetes Atlas. 3rd edn. Brussels: 2005. www.usmbha.org/Images/News/DA-promotion.pdf accessed 5-1-08
11. Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003;114:189-196
12. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002;45:1111-1119
13. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic patients. Diabetes 2003;52:380-386
14. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy patients. Diabetes 1995;44:1126-1131
15. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, ELahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-965
16. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-699
17. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287:E1209-E1215
18. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes treated for at least three years. Curr Med Res Opin 2008;24:275-286
19. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohant My, MD, Dandona P. exenatide therapy in obese patients with type2 diabetes mellitus treated with insulin. Endocr Pract 2007;13:5:444-450
20. Oyer DS, BettenHousen SK, Gallagher P. Exenatide use in multiple drug regimens: adjusting the Insulin and TZD presented ADA Annual meeting 2007;585-P
21. Loh JA, Clement SC. Efficacy of exenatide therapy over 12 months in a real world setting. Diabetes 2007;570-P
22. Kendall D, Blonde L, Mac S, Guan X-S, Holcombe J, Okerson T, Kim D, Bhole D. Improvements in cardiovascular risk factors accompanied improved glycemic control and weight reduction in patients with type 2 diabetes treated with exenatide for 3.5 y. Diabetes 2007;56:A149
23. Kim D, Maconell L, Zhuang D, Kothare PA. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 Diabetes. Diabetes Care 2007;30:1487-1493
24. Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, Verhoeven R, Bugánová I, Madsbad S. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-1610
25. Seino Y, Kaku K, Nishijima K, Rasmussen MF, Zdravkovic M, Kristersen P. Once Daily Dosing of the long acting GLP-1 analogue Liraglutide Significantly Improves Glycaemic Control by Reducing both Fasting and Post-Prandial Glucose Levels In Japanese Subjects With Type 2 Diabetes. Diabetes 2007;520-P
26. Kendall DM, Riddle MC, Rosenstock J. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091
27. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group. Sitagliptin add-on to glimepiride with or without metformin study. diabetes obes metab 2007;9:733-745
28. Rosenstock J, Pil-Sunyer FX, Prately RE, Couturier A, Schweizer A, Dejager S. Robust efficacy of vildagliptin in drug-naïve patients: pooled analysis of 5 monotherapy studies. Diabetes 2007;506-P
29. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88
30. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005;62:173-181
31. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635
32. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28: 1092-1100
33. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091
34. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88
35. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2006;8(4):436
36. Henry R, Ratner R, Stonehouse A, Guan X, Poon T, Malone J, Kim D, Kendall D. Exenatide Maintained glycemic control with associated weight reduction over 2 years in patients with type 2 diabetes. ADA Annual Meeting 2006. Abstract Number 485-P
37. Byetta (exenatide injection) (prescribing information). San Diego, CA: Amylin Pharmaceuticals. Inc 2006
38. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29:2333-2348
39. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-569
40. Madsbad S, Schmidt O, Ranstam J, Jakobsen G, Matthews DR, NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27:1335-1342
41. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874-2880
42. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes. Diabetes Care 2004;27:2874-2880
43. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-2940
44. Aschner P, Kipnes M, Lunceford J, Mickel C, Davies M, Williams-Herman D. Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes (T2DM) ADA Abstract: 2006 Abstract Number 1995-PO
45. Karasik A, Charbonnel B, Liu J, Wu M, Meehan A, Meininger G. Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes. ADA Abstract: 2006. Abstract Number 501-P
46. Rosenstock J, Brazg R, Andryuk P, Mccrary-Sisk C, Lu K, Stein P. Addition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM). ADA Abstract: 2006. Abstract Number 556-P
47. Scott R, Herman G, Zhao P, Chen X, Wu M, Stein P. Twelve week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of Type 2 diabetes (T2D). Diabetes 2005;54(Suppl 1):A10 Diabetes 2005;54(S1):A10
48. Panina G. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond. Diabetes Obes Metab 2007;9(Suppl 1):32-39
49. Personal communication with Amylin (makers of Exenatide) and Merck (makers of Sitagliptin) 4-2008
50. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health-Syst Pharm 2005;62:173-181
51. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88
52. Drucker DJ, Nouck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
53. Copeland KC, Becker D, Gottschalk M, Hale D. Type 2 diabetes in children and adolescents: risk factors, diagnosis, and treatment. Clinical Diabetes 2005;23:181-185